Skip to main content
. Author manuscript; available in PMC: 2011 Jan 1.
Published in final edited form as: J Pharm Pharmacol. 2010 Jan;62(1):145–151. doi: 10.1211/jpp.62.01.0017

Figure 3. JS-K inhibits HUVEC migration.

Figure 3

HUVEC migration at 5 hours with the indicated concentrations of JS-K was assayed using 10 ng/ml VEGF as a chemoattractant. JS-K treatment led to a dose-dependent inhibition of HUVEC migration. The IC50 for migration inhibition was 0.496 µM. At the 5-hours time point there was no evidence of growth inhibition. (Averages and SEM of 3 different experiments. Asterisks indicate statistically significant differences between treatments and control).